Anti-Human VEGF (Bevacizumab) - Fc Mutedâ„¢ HRP
£379.69
Anti-Human VEGF (Bevacizumab) - Fc Mutedâ„¢ HRP (LT407-100ug)
Product
| Cat # LT407-100ug | Size 100 µg |
Price
£379.69
|
Qty
|
Description
Bevacizumab is a monoclonal antibody that specifically recognizes vascular endothelial growth factor (VEGF). VEGF is a growth factor that participates in angiogenesis, vasculogenesis, and endothelial cell growth. It facilitates endothelial cell proliferation, cell migration, and the permeabilization of blood vessels. In addition, VEGF inhibits apoptosis. Bevacizumab neutralizes the biological activity of VEGF by preventing the interaction of VEGF with its receptors on the surface of endothelial cells, resulting in the regression of tumor vascularization, normalization of remaining tumor vasculature, and inhibition of the formation of new tumor vasculature, thus inhibiting tumor growth.1 Anti-Human VEGF (Bevacizumab) utilizes the same variable regions from the therapeutic antibody Bevacizumab making it ideal for research projects.
Specifications
| Manufacturer | Leinco Technologies Inc |
|---|---|
| Manufacturer Cat# | LT407 |
| Product Size | 100 µg |
| Concentration | 0.5 mg/ml |
| Formulation | This HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase) |
| Clone | A4.6.1 |
| Target | VEGF |
| Applications | ELISA, FC |
| Antigen | VEGF is widely expressed in the thyroid, prostate, and various other tissues. |
| Storage | This horseradish peroxidase conjugated monoclonal antibody is stable when stored at 2-8°C. Do not freeze. |
| Protein | VEGF |